Literature DB >> 11052622

Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.

Z Yang1, P J Faustino, P A Andrews, R Monastra, A A Rasmussen, C D Ellison, K J Cullen.   

Abstract

PURPOSE: To evaluate the correlation between cisplatin sensitivity, intracellular glutathione, and platinum/DNA adduct formation (measured by atomic absorption spectroscopy) in a series of seven head and neck cancer cell lines, and to evaluate the effect of biochemical modulation of glutathione on platinum/DNA adduct formation and repair.
METHODS: Cisplatin/DNA adducts were measured by atomic absorption spectroscopy. Glutathione content was measured by enzymatic assay and was modulated with buthionine sulfoximine. Apoptosis was measured by double-labeled flow cytometry.
RESULTS: Intracellular glutathione concentration was strongly correlated with cisplatin resistance (P = 0.002, R2 = 0.7). There was also a statistically significant inverse correlation between cisplatin/DNA adduct formation and the IC50 for cisplatin in these cell lines. (P = 0.0004, R2 = 0.67). In addition, resistant cells were able to repair approximately 70% of cisplatin/DNA adducts at 24 h, while sensitive cells repaired less than 28% of adducts in the same period. However, despite the positive correlation between cellular glutathione and cisplatin resistance, there was no direct correlation between intracellular glutathione concentration and platinum/DNA adduct formation. Further, depletion of intracellular glutathione by buthionine sulfoximine did not dramatically alter formation of cisplatin/DNA adducts even though it resulted in marked increase in cisplatin cytotoxicity and was associated with increased apoptosis.
CONCLUSIONS: These results suggest that glutathione has multiple effects not directly related to formation of cisplatin/DNA adducts, but may also be an important determinant of the cell's ability to repair cisplatin-induced DNA damage and resist apoptosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052622     DOI: 10.1007/s002800000167

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116.

Authors:  Thititip Tippayamontri; Rami Kotb; Benoit Paquette; Léon Sanche
Journal:  Invest New Drugs       Date:  2010-07-24       Impact factor: 3.850

2.  Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.

Authors:  Arpita Kulshrestha; Gajendra K Katara; Jordyn Ginter; Sahithi Pamarthy; Safaa A Ibrahim; Mukesh K Jaiswal; Corina Sandulescu; Ramayee Periakaruppan; James Dolan; Alice Gilman-Sachs; Kenneth D Beaman
Journal:  Mol Oncol       Date:  2016-01-29       Impact factor: 6.603

3.  Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism.

Authors:  Nataly Shulga; Robin Wilson-Smith; John G Pastorino
Journal:  Cell Cycle       Date:  2009-10-19       Impact factor: 4.534

4.  Hyperphosphorylation of replication protein A in cisplatin-resistant and -sensitive head and neck squamous cell carcinoma cell lines.

Authors:  Karoline C Manthey; Jason G Glanzer; Diana D Dimitrova; Greg G Oakley
Journal:  Head Neck       Date:  2010-05       Impact factor: 3.147

5.  Glucose deprivation increases nuclear DNA repair protein Ku and resistance to radiation induced oxidative stress in human cancer cells.

Authors:  Jie Li; Roashan Ayene; Kathleen M Ward; Eswarkumar Dayanandam; Iraimoudi S Ayene
Journal:  Cell Biochem Funct       Date:  2009-03       Impact factor: 3.685

6.  Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer.

Authors:  Ji-Youn Han; Eun Kyung Hong; Byung Gil Choi; Jin No Park; Ki Won Kim; Jin Hyung Kang; Jong-Youl Jin; Suk Young Park; Young Seon Hong; Kyung Shik Lee
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

7.  Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells.

Authors:  Makoto Adachi; Kei Ijichi; Yasuhisa Hasegawa; Hideaki Nakamura; Tetsuya Ogawa; Nobutake Kanematsu
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

Review 8.  Reduced glutathione: a radioprotector or a modulator of DNA-repair activity?

Authors:  Anupam Chatterjee
Journal:  Nutrients       Date:  2013-02-07       Impact factor: 5.717

Review 9.  Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer.

Authors:  Kevin J Cullen; Zejia Yang; Lisa Schumaker; Zhongmin Guo
Journal:  J Bioenerg Biomembr       Date:  2007-02       Impact factor: 3.853

10.  Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone.

Authors:  Lisa Schumaker; Nikolaos Nikitakis; Olga Goloubeva; Ming Tan; Rodney Taylor; Kevin J Cullen
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.